23%

Improvement in Medication Adherence Rate

33%

Capture of Quality of Life Score

47%

Reduction in EEG Abnormality Rate

44%

Increase in Neurologist Consultation Rate

Centralizes comparative insights on healthcare utilization and costs for long-acting (LA) vs. short-acting (SA) antiepileptic drug (AED) monotherapy. With detailed reports on drug effectiveness and patient outcomes, it empowers R&D professionals, scientists, and healthcare leaders to accelerate pharma business decisions through concrete, data-driven findings.